NASDAQ:RNA Avidity Biosciences (RNA) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free RNA Stock Alerts $25.52 +0.85 (+3.45%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$24.51▼$25.8550-Day Range$10.11▼$24.8352-Week Range$4.82▼$26.24Volume1.23 million shsAverage Volume1.23 million shsMarket Capitalization$2.03 billionP/E RatioN/ADividend YieldN/APrice Target$36.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media Get Avidity Biosciences alerts: Email Address Avidity Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside42.4% Upside$36.33 Price TargetShort InterestBearish10.81% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 2 Articles This WeekInsider TradingSelling Shares$4.15 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.07) to ($3.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.09 out of 5 starsMedical Sector779th out of 938 stocksPharmaceutical Preparations Industry357th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingAvidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.33, Avidity Biosciences has a forecasted upside of 42.4% from its current price of $25.52.Amount of Analyst CoverageAvidity Biosciences has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.81% of the outstanding shares of Avidity Biosciences have been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Avidity Biosciences has recently increased by 10.94%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNA. Previous Next 2.7 News and Social Media Coverage News SentimentAvidity Biosciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Avidity Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 20 people have searched for RNA on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows9 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,148,742.00 in company stock.Percentage Held by InsidersOnly 2.00% of the stock of Avidity Biosciences is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($3.07) to ($3.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvidity Biosciences has a P/B Ratio of 3.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Avidity Biosciences Stock (NASDAQ:RNA)Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Read More RNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNA Stock News HeadlinesMarch 16, 2024 | insidertrades.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells $980,800.00 in StockMarch 13, 2024 | insidertrades.comAvidity Biosciences, Inc. (NASDAQ:RNA) Director Sells $608,931.23 in StockMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 27, 2024 | prnewswire.comAvidity Biosciences to Participate in Upcoming Investor ConferencesMarch 17, 2024 | finance.yahoo.comRNA Apr 2024 17.500 callMarch 16, 2024 | finance.yahoo.comRNA Apr 2024 17.500 putMarch 16, 2024 | finance.yahoo.comRNA Apr 2024 22.500 callMarch 15, 2024 | finance.yahoo.comInsider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA)March 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 7, 2024 | markets.businessinsider.comAvidity Biosciences: Strong Buy Rating Amidst Positive Clinical Developments and Price Target SurgeMarch 5, 2024 | seekingalpha.comAvidity Biosciences: Targeting A First Ever Approval In DM1 With Improving DataMarch 5, 2024 | markets.businessinsider.comA Closer Look at 5 Analyst Recommendations For Avidity BiosciencesMarch 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Avidity Biosciences Following Promising MARINA-OLE Study Data and RNA AnalysisMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed: Avidity Biosciences’s Promising MARINA-OLE Trial Data Indicates Significant DM1 Treatment BreakthroughMarch 4, 2024 | msn.comAvidity Biosciences Says Lead Program Shows Reversal Of Disease Progression In Neuromuscular DiseaseMarch 4, 2024 | markets.businessinsider.comAvidity Accelerates Phase 3 HARBOR Study Initiation To Q2 - Quick FactsMarch 4, 2024 | finance.yahoo.comAvidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ TrialMarch 4, 2024 | finance.yahoo.comTop 2% Biotech Avidity Collapses Despite 'Positive' Results In Treating Muscular DystrophyMarch 2, 2024 | investing.comAvidity Biosciences secures $400 million in private placementMarch 1, 2024 | finance.yahoo.comAvidity Biosciences Full Year 2023 Earnings: Misses ExpectationsFebruary 29, 2024 | edition.cnn.comAvidity Biosciences IncFebruary 29, 2024 | seekingalpha.comAvidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-WatchFebruary 29, 2024 | prnewswire.comAvidity Biosciences Honors Rare Disease Day®February 29, 2024 | finanznachrichten.deAvidity Biosciences, Inc.: Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent HighlightsFebruary 29, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Avidity Biosciences (RNA)February 29, 2024 | prnewswire.comAvidity Biosciences Announces Oversubscribed $400 Million Private PlacementFebruary 29, 2024 | finance.yahoo.comAvidity Biosciences Inc (RNA) Reports Year-End Financials and Clinical ProgressSee More Headlines Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RNA CUSIPN/A CIK1574111 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees253Year FoundedN/APrice Target and Rating Average Stock Price Target$36.33 High Stock Price Target$60.00 Low Stock Price Target$20.00 Potential Upside/Downside+46.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-212,220,000.00 Net Margins-2,219.87% Pretax Margin-2,219.87% Return on Equity-39.74% Return on Assets-34.98% Debt Debt-to-Equity RatioN/A Current Ratio7.58 Quick Ratio7.58 Sales & Book Value Annual Sales$9.56 million Price / Sales206.72 Cash FlowN/A Price / Cash FlowN/A Book Value$6.76 per share Price / Book3.67Miscellaneous Outstanding Shares79,720,000Free Float78,125,000Market Cap$1.98 billion OptionableOptionable Beta0.72 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Troy Edward Wilson J.D. (Age 55)Ph.D., Co-Founder & Chairman Comp: $67.5kMs. Sarah Boyce (Age 52)President, CEO & Director Comp: $1.05MMr. Michael F. MacLean (Age 58)Chief Financial & Chief Business Officer Comp: $701.64kDr. W. Michael Flanagan Ph.D. (Age 62)Chief Scientific & Technical Officer Comp: $678.74kMs. Teresa McCarthy (Age 60)Chief Human Resources Officer Comp: $665.14kMr. Eric B. Mosbrooker (Age 56)Chief Strategy Officer Comp: $42.5kProf. Mark E. DavisScientific Founder, Member of Scientific Advisory Board and Member of Board of ManagersDr. Frank P. McCormick Ph.D. (Age 74)Scientific Founder & Member of Scientific Advisory Board Mr. Geoffrey M. Grande C.F.A.VP of Investor Relation & Corporate CommunicationDr. John W. Wallen III (Age 66)VP of Intellectual Property, General Counsel & Secretary More ExecutivesKey CompetitorsStructure TherapeuticsNASDAQ:GPCRCatalyst PharmaceuticalsNASDAQ:CPRXSchrödingerNASDAQ:SDGRJanux TherapeuticsNASDAQ:JANXSyndax PharmaceuticalsNASDAQ:SNDXView All CompetitorsInsiders & InstitutionsMichael F MacleanSold 40,000 sharesTotal: $980,800.00 ($24.52/share)Sarah BoyceSold 28,000 sharesTotal: $633,640.00 ($22.63/share)Arthur A LevinSold 27,641 sharesTotal: $608,931.23 ($22.03/share)Vanguard Group Inc.Bought 28,689 shares on 3/11/2024Ownership: 5.072%Sarah BoyceSold 84,000 sharesTotal: $1.80 M ($21.39/share)View All Insider TransactionsView All Institutional Transactions RNA Stock Analysis - Frequently Asked Questions Should I buy or sell Avidity Biosciences stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RNA shares. View RNA analyst ratings or view top-rated stocks. What is Avidity Biosciences' stock price target for 2024? 6 analysts have issued 1-year target prices for Avidity Biosciences' stock. Their RNA share price targets range from $20.00 to $60.00. On average, they predict the company's share price to reach $36.33 in the next twelve months. This suggests a possible upside of 42.4% from the stock's current price. View analysts price targets for RNA or view top-rated stocks among Wall Street analysts. How have RNA shares performed in 2024? Avidity Biosciences' stock was trading at $9.05 at the beginning of 2024. Since then, RNA shares have increased by 182.0% and is now trading at $25.52. View the best growth stocks for 2024 here. When is Avidity Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RNA earnings forecast. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) issued its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.25. The biotechnology company had revenue of $2.19 million for the quarter, compared to analysts' expectations of $32.08 million. Avidity Biosciences had a negative net margin of 2,219.87% and a negative trailing twelve-month return on equity of 39.74%. What ETFs hold Avidity Biosciences' stock? ETFs with the largest weight of Avidity Biosciences (NASDAQ:RNA) stock in their portfolio include Morningstar US Small Growth (MSGR) and Direxion Moonshot Innovators ETF (MOON).Simplify Propel Opportunities ETF (SURI). What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT). When did Avidity Biosciences IPO? Avidity Biosciences (RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO. Who are Avidity Biosciences' major shareholders? Avidity Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (9.33%), Price T Rowe Associates Inc. MD (9.33%), Vanguard Group Inc. (5.46%), Vanguard Group Inc. (5.07%), Artisan Partners Limited Partnership (2.84%) and Dimensional Fund Advisors LP (2.02%). Insiders that own company stock include Arthur A Levin, Michael F Maclean, Rtw Investments, Lp, Sarah Boyce and W Michael Flanagan. View institutional ownership trends. How do I buy shares of Avidity Biosciences? Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.